Johnson & Johnson (JNJ) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

Johnson & Johnson (JNJ)

270.24

+2.87 (1.07%)

as of Aug 21, 2026, 8:00:00 pm Market Open.

697 watching

Investor Insights

Aug 21, 2026, 12:00 am

This summary was created by AI, based on 10 opinions in the last 12 months.

Johnson & Johnson (JNJ) has shown some volatility recently, primarily due to performance issues in its cardio business, despite reporting a solid beat-and-raise quarter. The company has successfully addressed past legal challenges related to talcum powder, minimizing the overhang of these lawsuits. Analysts are optimistic about JNJ’s upcoming earnings report expected on July 15, anticipating positive news about its oncology drugs and orthopedic business, although caution persists due to erratic stock movements following disclosure of results. The spin-off of the orthopedics division is viewed positively as it shifts focus towards higher-margin pharmaceutical and medical device sectors. Overall, JNJ is seen as a solid investment due to its strong drug pipeline and improved balance sheet, even as the company navigates its litigation concerns.

Consensus

Buy

Valuation

Fair Value

Similar

TOP PICK

It's done relatively year. Their pharma pipeline remains strong and accounts for nearly half their revenues. The medical devices business is a recovery play as elective surgeries will see a ramp up after delays from Covid. JNJ will grow earnings in double-digits for the next couple years. It trades at a reasonable 17x PE. Has a strong balance sheet, and has raised its dividend for 58 straight years (now 2.5%). She likes healthcare long term. JNJ won't make much money off their vaccine, but their pharma pipeline is solid. (Analysts’ price target is $183.68)

BUY

They boast a long track record of paying dividends. They produced an approved one-shot Covid vaccine. JNJ has a good history of doing right for its shareholders. Great balance sheet and has a history of developing new job. JNJ won't make a lot of money off its Covid vaccine. It has the best balance sheet of any large company in the U.S.

SELL ON STRENGTH

Trades around 15x 2022, versus the market which is around 22x. A fine name to own with a decent dividend. Did very well during covid. He is looking to add to names that didn't do well during covid. It is not on his list for this reason. He would shave down and add money to more growth play.

TOP PICK

Dividend growth of 57 consecutive years. 3 divisions, plus vaccine rollout. Operates like a tax on the consumer. Continues to tick along. Possible acquisitions, especially on the device side. Yield is 2.56%. (Analysts’ price target is $183.68)

DON'T BUY

Very strong balance sheet, low debt to capital, a brand name. The only division that's clicking is pharma and the vaccine. Medical devices area has been hurt by Covid. Consumer side has taken a back seat, as many are buying generic brands. Talc litigation overhang.

BUY

Stock fell 4% when JNJ results results of their Covid vaccine A superb balance sheet, managers and product portfolio. Not concerned about their Covid vaccine results.

PAST TOP PICK

(A Top Pick Jan 08/20, Up 20%) Trades at 18x earnings and has increased its dividend for the last 54 years or so. They operate three businesses (personal care, pharmaceuticals, medical devices), so one segment lifts a sagging one, which is good. Has long owned this. He looks forward to their Covid vaccine phase 3 trial data in coming days. The vaccine won't make them a ton of money but will validate their R&D process. This stock will continue to do well.

Premium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK

(A Top Pick Sep 29/20, Up 12.5%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with JNJ has achieved the $165 target. We recommend trailing up the stop up from $132 to $147 (just above the original recommended entry level).

BUY

They report Tuesday and he expects a strong report as well as reveal positive Covid vaccine results.

PAST TOP PICK

(A Top Pick Dec 16/19, Up 16%) Has gained some altitude. There has been no shortage of negative headlines over the years. Pharmaceuticals is a litigious industry in general. A well diversified company. A slower growth pharma company. However, it is a wonderful company looking at durability. Valuation is just above their buy price of $148. Would wait for a pullback to enter.

BUY

Biden will protect Obamacare, which spells great news managed care companies. Healthcare will continue to be a major theme this year. JNJ especially is well-positioned for earnings, new products and their eventual vaccine.

DON'T BUY

The healthcare sector in general has been in the news a lot recently. He owned this one a couple of years ago. It is a diversified, broad exposure to pharma. There are, however, sectors of healthcare he likes better such as managed health care and devices.

BUY

It's fine. A cheap stock that will benefit from a weaker US dollar.

BUY

He bought it to increase his healthcare holdings. They have several business: prescriptions, medical devices, a huge consumer business, and vaccines. He's waiting for med. devices to pick up after operations resume globally after Covid. JNJ and Merck seem to lag the others in vaccines, but there'll be many opportunities to sell vaccines--vaccines will be a big winner for JNJ.

DON'T BUY

Looking at the technical structure of the stock, the 200-day moving average has been moving sideways. We are not seeing growth, similarly to Pfizer. There is a 5-6% growth rate but paying 17x forward price earnings. A good quality name but there is not enough growth.

Showing 151 to 165 of 628 entries

Most Recent Experts

Rob Sechan, Managing Partner, New Edge Capital

New Edge Capital

Jenny Harrington, CEO, Gilman Hill Asset Management

Gilman Hill Asset Management

Josh Brown, CEO, Ritholtz Wealth Management

Ritholtz Wealth Management

Amy Raskin, CIO, Chevy Chase Trust

Chevy Chase Trust

Darren Sissons

Campbell Lee & Ross

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Summer Sale

Johnson & Johnson (JNJ)